Anika Therapeutics reported $30.62M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Abbott USD 13.01B 423M Sep/2026
Agenus USD 33.7M 500K Mar/2026
Agios Pharmaceuticals USD 55.38M 10.64M Sep/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 450.82M 375.59M Sep/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Halozyme Therapeutics USD 492.97M 11.97M Sep/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 524.42M 98.93M Sep/2026
Integra LifeSciences USD 411.18M 7.62M Sep/2026
Intrexon USD 717K 511K Jun/2024
J&J USD 25.4B 89M Sep/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Ligand Pharmaceuticals USD 78.75M 4.95M Sep/2026
MacroGenics USD 32.83M 12.03M Jun/2026
Merit Medical Systems USD 416.24M 2.56M Sep/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 14.44B 2.49B Sep/2026
Smith & Nephew USD 1.6B 1.58B Jun/2026
Stryker USD 6.5B 100M Sep/2026
Veracyte USD 151.75M 1.43M Sep/2026
Xencor USD 116.52M 65.3M Sep/2026
Zimmer Biomet Holdings USD 2.06B 120M Sep/2026